Suppr超能文献

18F-FDG PET/CT上的总病变糖酵解(TLG)作为局部晚期直肠癌新辅助治疗后病理完全缓解的潜在预测指标:一项回顾性研究

Total Lesion Glycolysis (TLG) on 18F-FDG PET/CT as a Potential Predictor of Pathological Complete Response in Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy: A Retrospective Study.

作者信息

Tokmak Handan, Demir Nurhan, Çulpan Hazal Cansu

机构信息

Department of Nuclear Medicine, University of Health Sciences, Prof. Dr. Cemil Tascioglu Hospital, 34384 Şişli, Türkiye.

Istanbul Haseki Training and Research Hospital, 34096 Fatih, Türkiye.

出版信息

Diagnostics (Basel). 2025 Jul 16;15(14):1800. doi: 10.3390/diagnostics15141800.

Abstract

The accurate prediction of pathological complete response (pCR) following total neoadjuvant therapy (TNT) is crucial for optimising treatment protocols in locally advanced rectal cancer (LARC). Although conventional imaging techniques such as MRI show limitations in assessing treatment response, metabolic imaging utilising 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET-CT) provides distinctive information by quantifying tumour glycolytic activity. This study investigates the predictive value of sequential 18F-FDG PET-CT parameters, focusing on Total Lesion Glycolysis (TLG), in predicting pCR after TNT. We conducted a retrospective analysis of 33 LARC patients (T3-4/N0-1) treated with TNT (neoadjuvant-chemoradiation followed by consolidation FOLFOX chemotherapy). Sequential PET-CT scans were performed at baseline, interim (after 4 cycles of FOLFOX), and post-TNT. Metabolic parameters, including maximum standardised uptake value (SUVmax) and TLG, were measured. Receiver operating characteristic (ROC) analysis assessed the predictive performance of these parameters for pCR. The pCR rate was 21.2% (7/33). Post-TNT TLG ≤ 10 demonstrated excellent predictive accuracy for pCR (AUC 0.887, 92.3% sensitivity, 85.7% specificity, and 96.0% PPV), outperforming SUVmax (AUC 0.843). Interim TLG ≤ 10 also showed a strong predictive value (AUC 0.824, 100% sensitivity, and 71.4% specificity). TLG may serve as a reliable metabolic biomarker for predicting pathologic complete response (pCR) after total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC). Its inclusion in clinical decision-making could improve patient selection for organ preservation strategies, thereby reducing the need for unnecessary surgeries in the future. However, given that the study is based on a small retrospective design, the findings should be interpreted with caution and used alongside other decision-making tools until more comprehensive data are collected from larger studies.

摘要

新辅助治疗(TNT)后病理完全缓解(pCR)的准确预测对于优化局部晚期直肠癌(LARC)的治疗方案至关重要。尽管传统成像技术如MRI在评估治疗反应方面存在局限性,但利用18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET-CT)的代谢成像通过量化肿瘤糖酵解活性提供了独特信息。本研究调查了连续18F-FDG PET-CT参数,重点是总病变糖酵解(TLG),在预测TNT后pCR中的预测价值。我们对33例接受TNT治疗(新辅助放化疗后巩固性FOLFOX化疗)的LARC患者(T3-4/N0-1)进行了回顾性分析。在基线、中期(FOLFOX化疗4周期后)和TNT后进行了连续的PET-CT扫描。测量了包括最大标准化摄取值(SUVmax)和TLG在内的代谢参数。受试者操作特征(ROC)分析评估了这些参数对pCR的预测性能。pCR率为21.2%(7/33)。TNT后TLG≤10对pCR具有出色的预测准确性(AUC 0.887,敏感性92.3%,特异性85.7%,阳性预测值96.0%),优于SUVmax(AUC 0.843)。中期TLG≤10也显示出较强的预测价值(AUC 0.824,敏感性100%,特异性71.4%)。TLG可能是预测局部晚期直肠癌(LARC)新辅助治疗(TNT)后病理完全缓解(pCR)的可靠代谢生物标志物。将其纳入临床决策可以改善器官保留策略的患者选择,从而减少未来不必要手术的需求。然而,鉴于该研究基于小型回顾性设计,研究结果应谨慎解释,并与其他决策工具一起使用,直到从更大规模的研究中收集到更全面的数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/12293966/d023ad7d1110/diagnostics-15-01800-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验